ID   KB-V1
AC   CVCL_2089
SY   KB-v1; KB-V-1; KBV1
DR   BTO; BTO_0003917
DR   CLO; CLO_0007077
DR   CLDB; cl3009
DR   BioSample; SAMN03151732
DR   ChEMBL-Cells; CHEMBL4295414
DR   ChEMBL-Targets; CHEMBL4296451
DR   DSMZ; ACC-149
DR   DSMZCellDive; ACC-149
DR   PubChem_Cell_line; CVCL_2089
DR   Wikidata; Q54899567
RX   PubMed=2897240;
RX   PubMed=3711108;
RX   PubMed=7865904;
RX   PubMed=22118813;
WW   Info; ICLAC; -; https://iclac.org/wp-content/uploads/Cross-Contaminations_v13_distribution.xlsx
WW   Provider; NIH OTT; E-007-2006/0-6; https://web.archive.org/web/20150922130003/http://www.ott.nih.gov/erma/multidrug-resistant-epidermal-carcinoma-cell-line-kb-v-1
CC   Problematic cell line: Contaminated. Grand-parent cell line (KB) has been shown to be a HeLa derivative.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00373.
CC   Population: African American.
CC   Doubling time: ~50 hours (DSMZ=ACC-149).
CC   Selected for resistance to: ChEBI; CHEBI_27375; Vincaleukoblastine (Vinblastine).
CC   Transformant: NCBI_TaxID; 333761; Human papillomavirus type 18 (HPV18).
CC   Derived from site: In situ; Uterus, cervix; UBERON=UBERON_0000002.
ST   Source(s): DSMZ=ACC-149; PubMed=22118813
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 12,13.3 (DSMZ=ACC-149)
ST   D13S317: 12,14 (PubMed=22118813)
ST   D16S539: 9,10
ST   D18S51: 16
ST   D19S433: 13,14
ST   D21S11: 27,28
ST   D2S1338: 17
ST   D3S1358: 15,17,18
ST   D5S818: 11,12
ST   D7S820: 8,12
ST   D8S1179: 12,13
ST   FGA: 21
ST   Penta D: 8,15
ST   Penta E: 7,17
ST   TH01: 7
ST   TPOX: 8,12
ST   vWA: 16,18
DI   NCIt; C27677; Human papillomavirus-related endocervical adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2088 ! KB-3-1
SX   Female
AG   30Y6M
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 10-04-25; Version: 26
//
RX   PubMed=7865904;
RA   Zhang, Xiao-Ping
RA   Ritke, Mary K.
RA   Yalowich, Jack Charles
RA   Slovak, Marilyn L.
RA   Ho, Jennifer Pelkey
RA   Collins, Karen I.
RA   Annable, Tami
RA   Arceci, Robert John
RA   Durr, Frederick E.
RA   Greenberger, Lee M.
RT   "P-glycoprotein mediates profound resistance to bisantrene.";
RL   Oncol. Res. 6:291-301(1994).
//
RX   PubMed=3711108; DOI=10.1016/S0021-9258(19)57466-X;
RA   Shen, Ding-Wu
RA   Cardarelli, Carol O.
RA   Hwang, Jaulang
RA   Cornwell, Marilyn
RA   Richert, Nancy
RA   Ishii, Shunsuke
RA   Pastan, Ira
RA   Gottesman, Michael Marc
RT   "Multiple drug-resistant human KB carcinoma cells independently
RT   selected for high-level resistance to colchicine, adriamycin, or
RT   vinblastine show changes in expression of specific proteins.";
RL   J. Biol. Chem. 261:7762-7770(1986).
//
RX   PubMed=22118813; DOI=10.1016/j.canlet.2011.09.038;
RA   Krech, Till
RA   Scheuerer, Elisa
RA   Geffers, Robert
RA   Kreipe, Hans-Heinrich
RA   Lehmann, Ulrich
RA   Christgen, Matthias
RT   "ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of
RT   IPH-926 human lobular breast cancer cells.";
RL   Cancer Lett. 315:153-160(2012).
//
RX   PubMed=2897240; DOI=10.1016/0092-8674(88)90568-5;
RA   Choi, Kyunghee
RA   Chen, Chang-Jie
RA   Kriegler, Michael
RA   Roninson, Igor B.
RT   "An altered pattern of cross-resistance in multidrug-resistant human
RT   cells results from spontaneous mutations in the mdr1 (P-glycoprotein)
RT   gene.";
RL   Cell 53:519-529(1988).
//